DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR OMEPRAZOLE MAGNESIUM
» See Plans and Pricing
All Clinical Trials for Omeprazole Magnesium
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00206440 | Nexium Study To Suppress Nausea During Chemotherapy | Terminated | AstraZeneca | Phase 3 | 2005-08-01 | This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy. |
NCT00206440 | Nexium Study To Suppress Nausea During Chemotherapy | Terminated | Baylor Breast Care Center | Phase 3 | 2005-08-01 | This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy. |
NCT00693225 | Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study | Completed | Valeant Pharmaceuticals International, Inc. | Phase 4 | 2008-01-01 | The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal. |
NCT00693225 | Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study | Completed | Yvonne Romero | Phase 4 | 2008-01-01 | The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal. |
NCT01045434 | Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed Conditions | Completed | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-12-01 | An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover oral bioequivalence study of Omeprazole Magnesium 20 mg DR capsules of Dr. Reddy's Laboratories Limited, India and Prilosec OTCTM 20 mg (Omeprazole Magnesium DR Tablets)of Procter and Gamble, Cincinnati, Sweden in 38 healthy, adult, human subjects under fed conditions. |
NCT01045642 | Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsules Under Fasting Conditions | Completed | Dr. Reddy's Laboratories Limited | Phase 1 | 2006-12-01 | An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover oral bioequivalence study of Omeprazole Magnesium 20 mg DR Capsules of Dr. Reddy's Laboratories Limited, India and Prilosec OTCTM 20 mg (Omeprazole Magnesium DR Tablets) of Procter and Gamble, Cincinnati, Sweden in 38 healthy, adult, human subjects under fasting conditions. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Omeprazole Magnesium
Condition Name
Condition MeSH
Clinical Trial Locations for Omeprazole Magnesium
Trials by Country
Clinical Trial Progress for Omeprazole Magnesium
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Omeprazole Magnesium
Sponsor Name